Piantino P, Arosaio E
Divisione di Gastroenterologia, Osp. S. Giovanni Battista, Sede Molinette, Torino.
Scand J Clin Lab Invest Suppl. 1991;207:67-9. doi: 10.3109/00365519109104632.
Tumor-associated trypsin inhibitor (TATI) was assayed in serum of patients with gastroenterological diseases. Of the patients 92 had gastric cancer, 50 colonic cancer, 38 colitis, 36 polyposis of the colon, and 40 gastric ulcer. The cut-off level established on the basis of the mean concentration +3 SD of a reference population comprising 120 subjects was 32 micrograms/l. In gastric cancer TATI had a sensitivity and specificity similar to that of CA19-9, whereas its behavior in colon cancer was less satisfactory. Like other tumor markers TATI may be elevated in patients with inflammatory diseases. In our opinion TATI is a good tumor marker for gastric cancer and it is a useful complement to CEA and CA19-9.
对胃肠疾病患者的血清进行了肿瘤相关胰蛋白酶抑制剂（TATI）检测。其中92例为胃癌患者，50例为结肠癌患者，38例为结肠炎患者，36例为结肠息肉病患者，40例为胃溃疡患者。基于120名受试者组成的参考人群的平均浓度+3标准差确定的临界值为32微克/升。在胃癌中，TATI的敏感性和特异性与CA19-9相似，而其在结肠癌中的表现则不太理想。与其他肿瘤标志物一样，炎症性疾病患者的TATI可能会升高。我们认为TATI是一种很好的胃癌肿瘤标志物，是癌胚抗原（CEA）和CA19-9的有用补充。
